Uncategorized

Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.

The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.

The medical device maker grew revenue by double digits in its fiscal first quarter, following fourth-quarter growth of nearly 10%.

GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.

The systems agreed to 10 years of state oversight and $600 million in investments as South Dakota-based Sanford moves into the Twin Cities.

The certification positions GE HealthCare to challenge Siemens Healthineers for the European market.

After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as part of a strategic shift to focus the company’s R&D efforts on in vivo CAR T therapies.

Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases of immune effector cell-associated hemophagocytic syndrome. BMS, meanwhile, paused some CAR T trials after separately observing “transient and reversible inflammatory events” with its therapy.

Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program, representing some 89% of the branded drug market.

Manadas de cíborgs de cucaracha con cámaras e inyectores médicos miniaturizados podrían brindar atención de emergencia supervisada a personas atrapadas en edificios derrumbados, cuevas u otros lugares demasiado estrechos para que el personal humano de rescate pueda …